• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Belsomra: A New Hypnotic? Don’t Get Too Excited

Belsomra: A New Hypnotic? Don’t Get Too Excited

October 1, 2014
Talia Puzantian, PharmD, BCPP
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Talia Puzantian, PharmD, BCPP Clinical psychopharmacology consultant in private practice, Los Angeles, CA. www.taliapuzantian.com Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
In the wake (pun intended) of last year’s FDA warnings of next-morning impairment and the lower dosing recommendations for “Z drugs,” wouldn’t now be the perfect time for a new hypnotic to enter the marketplace?

Suvorexant, which will be marketed by Merck & Co. under the brand name Belsomra, was approved by the FDA in August 2014. It truly is a new chemical entity with a first-in-kind mechanism of action. Unlike currently marketed hypnotics, suvorexant does not exert its hypnotic effects via activity at receptors for GABA, histamine, or melatonin. Considered a “DORA” or dual orexin (OX1 and OX2) receptor antagonist, suvorexant alters the signaling of orexins. Orexins are neurotransmitters that regulate the sleep-wake cycle by promoting wakefulness through excitement of brain regions involved in arousal and attention.

But what does this mean clinically? Does it work? Is it safe? What about long-term use?

What Studies Show

Several pre-clinical trials have examined the efficacy and safety of suvorexant in 1,784 patients with insomnia, with 160 patients taking the drug for one year or longer. Compared to patients taking placebo, those taking suvorexant tended to go to sleep more quickly (depending on the study and the dosage used, an average of about two to 22 minutes faster) and spent less time awake throughout the night (on average, about 20 minutes more total sleep time). In general, the higher doses (30 mg to 40 mg) tended to be more effective than the lower doses (15 mg to 20 mg). These studies all compared suvorexant with placebo, so unfortunately there is no data allowing us to compare it with the hypnotics currently in use.

The most common side effects were somnolence, headache, abnormal dreams, and dry mouth, which were reported in about 2% to 8% of patients in the studies. There were also some rare side effects (reported in less than 1% of patients) that could become quite problematic. These include sleep paralysis (inability to speak or move for up to a few minutes during the sleep-wake transition), cataplexy (leg weakness for seconds up to a few minutes, reported both in the nighttime and daytime), and hypnagogic hallucinations (including vivid and disturbing perceptions).

The Fight for FDA Approval

An interesting part of the history of this drug is that Merck expected to gain FDA approval in the summer of 2013. However, the FDA expressed concerns about safety with the 30 mg to 40 mg dosing range Merck was proposing and denied approval. The approval finally came in August with the newer, lower dosing range of 10 mg to 20 mg nightly. The next-day driving tests requested by the FDA showed that even those who took the 20 mg dose were impaired in the morning. For this reason, the recommended dose is 10 mg nightly, however, the labeling does allow for dosage increases up to 20 mg nightly. Along with the concern for next-day impairment, the usual warnings for hypnotics also apply here: avoid alcohol and other CNS depressants, exercise caution in patients who are depressed or suicidal, monitor for behavioral changes including amnesia and complex sleep behaviors (eating, texting, sex while still sleeping).

Suvorexant will be available as 5, 10, 15, and 20 mg tablets by late 2014 or early 2015. It will be a schedule IV controlled substance (same category as zolpidem (Ambien) and temazepam (Restoril), among others) although the data thus far have not shown withdrawal and rebound upon discontinuation.

TCPR’s Verdict: Other than a new mechanism of action, there’s not much to recommend suvorexant. It likely works just fine as a sleeping pill, but there’s no reason to expect it to work better than the many hypnotics already on the market. We’re concerned that next-day impairment is a potential side effect at the highest approved dose of 20 mg, particularly since sleepless patients may decide on their own to take even higher doses. Be very clear to patients about the potential dangers of driving the next morning. Suvorexant also will likely be expensive, and only a couple of thousand people have been exposed thus far, mostly in short-term trials. This is definitely not a first line medication—nor even a second line.
General Psychiatry
KEYWORDS sleep_disorders
Puzantian 150x150
Talia Puzantian, PharmD, BCPP

Treating Alcohol Use Disorder—A Fact Book (2023)

More from this author
www.thecarlatreport.com
Issue Date: October 1, 2014
SUBSCRIBE NOW
Table Of Contents
Sunshine Linked to Suicide Rates
Research Indicates Schizophrenia is Eight Distinct Disorders
Pharmacogenetic Testing in Clinical Psychiatry
Belsomra: A New Hypnotic? Don’t Get Too Excited
The Uses of Pharmacogenetic Testing
Physicians May Overprescribe Antidepressants Based on Brief Depression Questionnaires
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.